市場調査レポート
商品コード
1173997

医薬品原薬の世界市場:種類別 (革新的、ジェネリック)・メーカー別 (自社用・外販用)・合成別 (合成、バイオテクノロジー)、製品別 (モノクローナル抗体、ホルモン、サイトカイン)・薬剤別 (市販薬、処方薬)・用途別 (糖尿病、腫瘍、CVD) の将来予測 (2027年まで)

Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormones, Cytokines), Drug (OTC,Rx) Application (Diabetes, Oncology, CVD) - Global Forecast to 2027

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 361 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
医薬品原薬の世界市場:種類別 (革新的、ジェネリック)・メーカー別 (自社用・外販用)・合成別 (合成、バイオテクノロジー)、製品別 (モノクローナル抗体、ホルモン、サイトカイン)・薬剤別 (市販薬、処方薬)・用途別 (糖尿病、腫瘍、CVD) の将来予測 (2027年まで)
出版日: 2022年12月02日
発行: MarketsandMarkets
ページ情報: 英文 361 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の医薬品原薬 (API) の市場規模は、2022年には1,459億米ドル、2027年には2,164億米ドルに達し、予測期間中に8.2%のCAGRで成長すると予測されています。

バイオ医薬品の導入件数の増加、ジェネリック医薬品の重要性の増加、精密医療への関心増大といった要因が、世界のAPI市場の成長を促進する主な要因となっています。

合成の種類別に見ると、2021年には合成APIが最大のシェアを占めています。しかし、バイオテクノロジーAPIのセグメントも予測期間中に高い成長率で成長する見通しです。作用の特異性によるバイオ医薬品の需要拡大や、バイオテクノロジーの進歩などの要因が、市場の成長を後押ししています。

製品別に見ると、2021年にはモノクローナル抗体分野がバイオテクノロジーAPI市場で最大のシェアを占めると推定されています。

地域別に見ると、2021年には北米が市場を独占し、欧州がそれに続いています。この地域のAPI市場全体の成長を促す主な要因としては、大手の製薬・バイオ医薬品製造施設の存在や、ジェネリック医薬品に対する政府の関心の高まり、生物製剤および特殊医薬品の需要増加、APIの製造工程における技術進歩が挙げられます。

当レポートでは、世界の医薬品原薬の市場について分析し、市場の基本構造や最新情勢、主な市場促進・抑制要因、種類別・薬理活性別・合成の種類別・医薬品の種類別・治療用途別・地域別の市場動向の見通し、市場競争の状態、主要企業のプロファイルなどを調査しております。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
  • バリューチェーン分析
  • サプライチェーン分析
  • エコシステム分析:医薬品原薬市場
  • 特許分析
  • 主な会議とイベント
  • 関税と規制の状況
  • ポーターのファイブフォース分析
  • 主な利害関係者と購入基準
  • 価格分析
  • 貿易分析

第6章 医薬品原薬市場:種類別

  • イントロダクション
  • 医薬品原薬 (自社用・外販用):種類別
  • 革新的API
  • ジェネリックAPI

第7章 医薬品原薬市場:薬理活性別

  • イントロダクション
  • 従来型API
  • 高薬理活性API (HPAPI)

第8章 医薬品原薬市場:合成の種類別

  • イントロダクション
  • 医薬品原薬 (自社用・外販用):合成の種類別
  • 合成API
    • 種類別
  • バイオテクノロジーAPI
    • 種類別
    • 製品別
    • 発現システム別

第9章 医薬品原薬市場:医薬品の種類別

  • イントロダクション
  • 処方薬
  • 市販薬

第10章 医薬品原薬市場:治療用途別

  • イントロダクション
  • 感染症
  • 腫瘍
  • 糖尿病
  • 心血管疾患
  • 疼痛管理
  • 呼吸器疾患
  • その他の治療への適用

第11章 医薬品原薬市場:地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ハンガリー
    • 他の欧州諸国
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • 他のアジア太平洋諸国
  • 他の国々 (RoW)
    • イスラエル
    • 他の国々

第12章 競合情勢

  • 概要
  • 主要企業が採用した戦略
  • 市場シェア分析
  • 大手企業の収益シェア分析
  • 企業評価クアドラント
  • スタートアップ/中小企業向け企業評価クアドラント
  • 企業の地域フットプリント
  • 競合シナリオ

第13章 企業プロファイル

  • 主要企業
    • PFIZER INC.
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • DIVI'S LABORATORIES LIMITED
    • VIATRIS INC.
    • NOVARTIS AG
    • SANOFI
    • BOEHRINGER INGELHEIM
    • BRISTOL-MYERS SQUIBB
    • ELI LILLY AND COMPANY
    • GLAXOSMITHKLINE PLC
    • MERCK & CO., INC.
    • ABBVIE INC.
    • F. HOFFMANN-LA ROCHE LTD.
    • ASTRAZENECA
    • DR. REDDY'S LABORATORIES LTD.
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
    • CIPLA INC.
    • AUROBINDO PHARMA
    • EVONIK INDUSTRIES AG
  • その他の企業
    • API PHARMA TECH
    • BDR PHARMACEUTICALS INTERNATIONALS PVT. LTD.
    • SREEPATHI PHARMACEUTICALS LIMITED
    • SHILPA MEDICARE LIMITED

第14章 付録

目次
Product Code: PH 1262

The global Active Pharmaceutical Ingredient (APIs) market is estimated to reach USD 145.9 billion by 2022 to USD 216.4 billion in 2027, at a CAGR of 8.2% during the forecast period. Factors such as the increasing uptake of biopharmaceuticals, the growing importance of generics, and the rising focus on precision medicine are some of the major factors driving the growth of the global APIs market.

"The biotech APIs segment is expected to grow at the highest CAGR during the forecast period."

On the basis of the type of synthesis, the APIs market is categorized into synthetic APIs and biotech APIs. In 2021, the synthetic APIs segment accounted for the largest share. However, the biotech APIs segment is expected to grow at a higher rate over the forecast period. Factors such as the growing demand for biotech drugs due to their specificity in action and advancements in biotechnology are driving market growth in the market.

"The monoclonal antibodies segment is expected to account for the largest share of the global biotech APIs market."

Based on product, the biotech APIs market is segmented into monoclonal antibodies, hormones & growth factors, cytokines, fusion proteins, therapeutic enzymes, recombinant vaccines, and blood factors. In 2021, the monoclonal antibodies segment was estimated to account for the largest share of the biotech APIs market.

"North America to dominate the market during the forecast period."

In 2021, North America dominated the market, followed by Europe. The major factors driving the overall growth of the APIs market in this region include the presence of major pharmaceutical and biopharmaceutical manufacturing facilities, an increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures as well as the introduction of low-cost and generic versions of branded drugs.

Breakdown of the profile of primary participants:

  • By Company Type: Tier 1 - 37%, Tier 2 - 22%, and Tier 3 - 41%
  • By Designation: C-level Executives - 25%, Directors - 20%, Others - 55%
  • By Region: North America - 40%, Europe - 27%, Asia Pacific - 20%, and RoW - 13%

List of companies profiled in the report

  • Pfizer, Inc. (US),
  • Novartis AG (Switzerland),
  • Sanofi (France),
  • Boehringer Ingelheim (Germany),
  • Bristol-Myers Squibb (US),
  • Teva Pharmaceutical Industries Ltd. (Israel),
  • Eli Lilly and Company (US),
  • GlaxoSmithKline plc (UK),
  • Merck & Co., Inc. (US),
  • AbbVie Inc. (US),
  • F. Hoffmann-La Roche Ltd. (Switzerland),
  • AstraZeneca (UK),
  • Cipla, Inc. (India),
  • Mylan N.V. (US),
  • Dr. Reddy's Laboratories Ltd. (India),
  • Sun Pharmaceutical Industries Ltd. (India),
  • API Pharma Tech (India),
  • BDR Pharmaceuticals Internationals Pvt. Ltd. (India),
  • Sreepathi Pharmaceuticals Limited (India),
  • Shilpa Medicare Limited (India),
  • Evonik Industries AG (Germany),
  • Aurobindo Pharma Limited (India).

Research Coverage:

This report provides a picture of the global APIs market. It aims at estimating the size and future growth potential of the market across different segments, such as type, potency, type of synthesis, type of drug, therapeutic application, and region. Furthermore, the report also includes an in-depth competitive analysis of key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall APIs market and its subsegments. Also, this report will help stakeholders to better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 MARKET SEGMENTATION
    • 1.3.2 GEOGRAPHIC SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
    • FIGURE 5 MARKET SIZE ESTIMATION: DEMAND-SIDE ANALYSIS
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 ASSUMPTIONS

3 EXECUTIVE SUMMARY

    • FIGURE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2022 VS. 2027 (USD BILLION)
    • FIGURE 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY TYPE OF SYNTHESIS, 2021
    • FIGURE 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2022 VS. 2027 (USD BILLION)
    • FIGURE 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2022 VS. 2027 (USD BILLION)
    • FIGURE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY THERAPEUTIC APPLICATION, 2021
    • FIGURE 12 GEOGRAPHICAL SNAPSHOT OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET

4 PREMIUM INSIGHTS

  • 4.1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET OVERVIEW
    • FIGURE 13 INCREASING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
  • 4.2 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE AND COUNTRY (2021)
    • FIGURE 14 INNOVATIVE APIS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
  • 4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 15 ASIA PACIFIC TO WITNESS HIGHEST GROWTH IN FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 16 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Pharmaceutical and biopharmaceutical capacity expansion
      • 5.2.1.2 Growing importance of generics
    • TABLE 1 INDICATIVE LIST OF DRUGS GOING GENERIC IN 2021
      • 5.2.1.3 Increasing uptake of biopharmaceuticals
    • TABLE 2 US: INDICATIVE LIST OF BIOLOGICS THAT GAINED REGULATORY APPROVAL IN 2021
      • 5.2.1.4 Technological advancements in API manufacturing
      • 5.2.1.5 Focus on precision medicine
      • 5.2.1.6 Increasing incidence of chronic diseases
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Complications during API manufacturing
      • 5.2.2.2 Low profit margins and high manufacturing costs
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Emerging biosimilars market
    • TABLE 3 US: INDICATIVE LIST OF BIOSIMILARS THAT GAINED REGULATORY APPROVAL (2021-2022)
      • 5.2.3.2 Highly potent active pharmaceutical ingredients
      • 5.2.3.3 Emerging markets
      • 5.2.3.4 Emerging technologies/processes
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Increasing penetration of counterfeit drugs
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 17 MAJOR VALUE ADDED DURING MANUFACTURING
  • 5.4 SUPPLY CHAIN ANALYSIS
    • FIGURE 18 DIRECT DISTRIBUTION-STRATEGY PREFERRED BY PROMINENT COMPANIES
  • 5.5 ECOSYSTEM ANALYSIS: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
    • FIGURE 19 ECOSYSTEM ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET
  • 5.6 PATENT ANALYSIS
    • FIGURE 20 PATENT APPLICATIONS FOR ACTIVE PHARMACEUTICAL INGREDIENTS, JANUARY 2010-DECEMBER 2021
  • 5.7 KEY CONFERENCES AND EVENTS
    • TABLE 4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS, 2022-2023
  • 5.8 TARIFF AND REGULATORY LANDSCAPE
    • 5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF SUPPLIERS
    • 5.9.4 BARGAINING POWER OF BUYERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ACTIVE PHARMACEUTICAL INGREDIENTS
    • 5.10.2 BUYING CRITERIA FOR ACTIVE PHARMACEUTICAL INGREDIENTS
    • FIGURE 22 KEY BUYING CRITERIA FOR END USERS
  • 5.11 PRICING ANALYSIS
    • TABLE 9 IMPORTERS FOR ANTIBIOTICS (HS CODE - 2941)
    • TABLE 10 EXPORTERS FOR ANTIBIOTICS (HS CODE - 2941)
    • TABLE 11 IMPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE - 2934)
    • TABLE 12 EXPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE - 2934)
    • TABLE 13 IMPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE - 2937)
    • TABLE 14 EXPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE - 2937)
  • 5.12 TRADE ANALYSIS
    • TABLE 15 TOP 10 IMPORTERS FOR ANTIBIOTICS (HS CODE - 2941)
    • TABLE 16 TOP 10 EXPORTERS OF ANTIBIOTICS (HS CODE - 2941)
    • TABLE 17 TOP 10 IMPORTERS OF NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE - 2934)
    • TABLE 18 TOP 10 EXPORTERS OF NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE - 2934)
    • TABLE 19 TOP 10 IMPORTERS OF HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE - 2937)
    • TABLE 20 TOP 10 EXPORTERS OF HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE - 2937)

6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 21 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
  • 6.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE (CAPTIVE AND MERCHANT)
    • TABLE 22 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2020-2027 (USD BILLION)
    • TABLE 23 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
  • 6.3 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS
    • 6.3.1 GROWING NUMBER OF NEW MOLECULAR ENTITIES GAINING REGULATORY APPROVALS TO DRIVE MARKET
    • TABLE 24 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 25 NORTH AMERICA: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 26 EUROPE: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 27 ASIA PACIFIC: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 28 REST OF THE WORLD: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
  • 6.4 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS
    • 6.4.1 GOVERNMENT INITIATIVES SUPPORTING ADOPTION OF GENERIC DRUGS TO BOOST MARKET GROWTH
    • TABLE 29 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 30 NORTH AMERICA: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 31 EUROPE: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 32 ASIA PACIFIC: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 33 REST OF THE WORLD: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)

7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY

  • 7.1 INTRODUCTION
    • TABLE 34 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
  • 7.2 TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS
    • 7.2.1 APPLICATION IN VARIOUS THERAPEUTIC AREAS TO SUPPORT MARKET GROWTH
    • TABLE 35 TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 36 NORTH AMERICA: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 37 EUROPE: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 38 ASIA PACIFIC: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 39 REST OF THE WORLD: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
  • 7.3 HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS
    • 7.3.1 INCREASING APPLICATION ACROSS RANGE OF THERAPEUTIC AREAS TO DRIVE MARKET
    • TABLE 40 HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 41 NORTH AMERICA: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 42 EUROPE: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 43 ASIA PACIFIC: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 44 REST OF THE WORLD: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)

8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS

  • 8.1 INTRODUCTION
    • TABLE 45 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
  • 8.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT)
    • TABLE 46 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT), 2020-2027 (USD BILLION)
    • TABLE 47 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
  • 8.3 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS
    • TABLE 48 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 49 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 50 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 51 ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 52 REST OF THE WORLD: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • 8.3.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
    • TABLE 53 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
      • 8.3.1.1 Innovative synthetic APIs
        • 8.3.1.1.1 High value of innovative APIs to drive market
    • TABLE 54 INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 55 NORTH AMERICA: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 56 EUROPE: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 57 ASIA PACIFIC: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 58 REST OF THE WORLD: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
      • 8.3.1.2 Generic synthetic APIs
        • 8.3.1.2.1 Initiatives to promote penetration of generics to support market growth
    • TABLE 59 GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 60 NORTH AMERICA: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 61 EUROPE: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 62 ASIA PACIFIC: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 63 REST OF THE WORLD: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
  • 8.4 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS
    • TABLE 64 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 65 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 66 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 67 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 68 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • 8.4.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE
    • TABLE 69 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
      • 8.4.1.1 Innovative biotech APIs
        • 8.4.1.1.1 Growing demand for innovative biopharmaceuticals to drive market
    • TABLE 70 INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 71 NORTH AMERICA: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 72 EUROPE: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 73 ASIA PACIFIC: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 74 REST OF THE WORLD: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
      • 8.4.1.2 Generic biotech APIs
        • 8.4.1.2.1 Increasing demand for biosimilar drugs due to cost-effectiveness to drive market
    • TABLE 75 GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 76 NORTH AMERICA: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 77 EUROPE: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 78 ASIA PACIFIC: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 79 REST OF THE WORLD: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • 8.4.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT
    • TABLE 80 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
      • 8.4.2.1 Monoclonal antibodies
        • 8.4.2.1.1 Growing applications of antibody-drug conjugates in treatment of cancer to drive growth
    • TABLE 81 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 82 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 83 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 84 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 85 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020-2027 (USD BILLION)
      • 8.4.2.2 Hormones and growth factors
        • 8.4.2.2.1 Growing incidence of hormonal disorders to drive market
    • TABLE 86 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 87 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 88 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 89 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 90 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020-2027 (USD BILLION)
      • 8.4.2.3 Cytokines
        • 8.4.2.3.1 Interferons and interleukins boost immune system
    • TABLE 91 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 92 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 93 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 94 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 95 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2020-2027 (USD BILLION)
      • 8.4.2.4 Fusion proteins
        • 8.4.2.4.1 Growing applications of fusion proteins in biopharmaceuticals to drive market
    • TABLE 96 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 97 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 98 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 99 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 100 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2020-2027 (USD BILLION)
      • 8.4.2.5 Recombinant vaccines
        • 8.4.2.5.1 Growing prevalence of infectious diseases to boost vaccine development
    • TABLE 101 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 102 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 103 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 104 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 105 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020-2027 (USD BILLION)
      • 8.4.2.6 Therapeutic enzymes
        • 8.4.2.6.1 Growing significance of enzymes in therapies for cancer and pain management to drive market
    • TABLE 106 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 107 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 108 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 109 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 110 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, 2020-2027 (USD BILLION)
      • 8.4.2.7 Blood factors
        • 8.4.2.7.1 Growing incidence of hemophilia to drive market
    • TABLE 111 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 112 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 113 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 114 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 115 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, 2020-2027 (USD BILLION)
    • 8.4.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM
    • TABLE 116 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
      • 8.4.3.1 Mammalian expression systems
        • 8.4.3.1.1 Ability to carry post-translational modifications to drive adoption
    • TABLE 117 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 118 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 119 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 120 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 121 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
      • 8.4.3.2 Microbial expression systems
        • 8.4.3.2.1 High expression levels of proteins at low costs to drive market
    • TABLE 122 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 123 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 124 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 125 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 126 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
      • 8.4.3.3 Yeast expression systems
        • 8.4.3.3.1 Efficient protein secretion, simple purification, and endotoxin-free products to boost demand
    • TABLE 127 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 128 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 129 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 130 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 131 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
      • 8.4.3.4 Insect expression systems
        • 8.4.3.4.1 Efficient post-translational modifications to boost adoption
    • TABLE 132 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 133 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 134 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 135 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 136 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
      • 8.4.3.5 Other expression systems
    • TABLE 137 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 138 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 139 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 140 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 141 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION)

9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG

  • 9.1 INTRODUCTION
    • TABLE 142 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
  • 9.2 PRESCRIPTION DRUGS
    • 9.2.1 GROWING DISEASE PREVALENCE TO SUPPORT MARKET GROWTH
    • TABLE 143 PRESCRIPTION DRUGS MARKET, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 144 NORTH AMERICA: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 145 EUROPE: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 146 ASIA PACIFIC: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 147 REST OF THE WORLD: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
  • 9.3 OVER-THE-COUNTER DRUGS
    • 9.3.1 INCREASED SALES OF OTC DRUGS DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS
    • TABLE 148 OVER-THE-COUNTER DRUGS MARKET, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 149 NORTH AMERICA: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 150 EUROPE: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 151 ASIA PACIFIC: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 152 REST OF THE WORLD: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)

10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION

  • 10.1 INTRODUCTION
    • TABLE 153 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
  • 10.2 COMMUNICABLE DISEASES
    • 10.2.1 LARGEST AND FASTEST-GROWING MARKET SEGMENT
    • TABLE 154 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 155 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 156 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 157 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 158 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020-2027 (USD BILLION)
  • 10.3 ONCOLOGY
    • 10.3.1 INCREASING SPENDING ON CANCER MEDICATION TO SUPPORT MARKET GROWTH
    • TABLE 159 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 160 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 161 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 162 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 163 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD BILLION)
  • 10.4 DIABETES
    • 10.4.1 HIGH PREVALENCE OF DIABETES TO DRIVE MARKET
    • TABLE 164 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 165 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 166 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 167 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 168 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2020-2027 (USD BILLION)
  • 10.5 CARDIOVASCULAR DISEASES
    • 10.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES
    • TABLE 169 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 170 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 171 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 172 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 173 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD BILLION)
  • 10.6 PAIN MANAGEMENT
    • 10.6.1 INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS TO PROPEL MARKET
    • TABLE 174 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 175 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 176 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 177 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 178 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020-2027 (USD BILLION)
  • 10.7 RESPIRATORY DISEASES
    • 10.7.1 HIGH PREVALENCE OF RESPIRATORY DISEASES TO SUPPORT MARKET GROWTH
    • TABLE 179 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 180 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 181 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 182 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 183 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020-2027 (USD BILLION)
  • 10.8 OTHER THERAPEUTIC APPLICATIONS
    • TABLE 184 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2020-2027 (USD BILLION)
    • TABLE 185 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 186 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 187 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 188 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD BILLION)

11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION

  • 11.1 INTRODUCTION
    • TABLE 189 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION)
  • 11.2 NORTH AMERICA
    • FIGURE 23 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
    • TABLE 190 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 191 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 192 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 USD BILLION)
    • TABLE 193 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 194 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 195 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 196 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 197 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 198 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 199 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.2.1 US
      • 11.2.1.1 Largest market for active pharmaceutical ingredients
    • TABLE 200 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 201 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 202 US: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 203 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 204 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 205 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 206 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 207 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 208 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.2.2 CANADA
      • 11.2.2.1 Growing pharmaceutical manufacturing to support market growth
    • TABLE 209 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 210 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 211 CANADA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 212 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 213 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 214 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 215 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 216 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 217 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
  • 11.3 EUROPE
    • TABLE 218 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 219 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 220 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 221 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 222 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 223 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 224 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 225 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 226 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 227 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.3.1 GERMANY
      • 11.3.1.1 Leading country in terms of infrastructure and competency for R&D
    • TABLE 228 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 229 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 230 GERMANY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 231 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 232 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 233 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 234 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 235 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 236 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.3.2 FRANCE
      • 11.3.2.1 Healthy pharmaceutical production to support API demand
    • TABLE 237 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 238 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 239 FRANCE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 240 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 241 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 242 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 243 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 244 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 245 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.3.3 UK
      • 11.3.3.1 Rising government investments to drive market
    • TABLE 246 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 247 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 248 UK: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 249 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 250 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 251 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 252 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 253 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 254 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.3.4 ITALY
      • 11.3.4.1 Growing investment in API production to support market growth
    • TABLE 255 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 256 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 257 ITALY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 258 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 259 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 260 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 261 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 262 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 263 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.3.5 SPAIN
      • 11.3.5.1 Increase in generic drug manufacturing capacity to propel demand for APIs
    • TABLE 264 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 265 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 266 SPAIN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 267 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 268 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 269 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 270 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 271 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 272 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.3.6 HUNGARY
      • 11.3.6.1 Rising incidence of chronic diseases to propel market growth
    • TABLE 273 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 274 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 275 HUNGARY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 276 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 277 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 278 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 279 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 280 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 281 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.3.7 REST OF EUROPE
    • TABLE 282 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 283 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 284 REST OF EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 285 REST OF EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 286 REST OF EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 287 REST OF EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 288 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 289 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 290 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
  • 11.4 ASIA PACIFIC
    • FIGURE 24 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT
    • TABLE 291 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 292 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 293 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 294 ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 295 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 296 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 297 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 298 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 299 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 300 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.4.1 JAPAN
      • 11.4.1.1 Presence of large pharmaceutical companies to propel market
    • TABLE 301 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 302 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 303 JAPAN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 304 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 305 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 306 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 307 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 308 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 309 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.4.2 CHINA
      • 11.4.2.1 Government policies to increase medicine access and affordability to support market growth
    • TABLE 310 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 311 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 312 CHINA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 313 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 314 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 315 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 316 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 317 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 318 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.4.3 INDIA
      • 11.4.3.1 Leading producer of generics
    • TABLE 319 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 320 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 321 INDIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 322 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 323 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 324 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 325 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 326 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 327 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.4.4 SOUTH KOREA
      • 11.4.4.1 Rising annual drug exports to drive market
    • TABLE 328 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 329 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 330 SOUTH KOREA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 331 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 332 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 333 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 334 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 335 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 336 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.4.5 REST OF ASIA PACIFIC
    • TABLE 337 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 338 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 339 REST OF ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 340 REST OF ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 341 REST OF ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 342 REST OF ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 343 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 344 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 345 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
  • 11.5 REST OF THE WORLD
    • TABLE 346 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION)
    • TABLE 347 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 348 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 349 REST OF THE WORLD: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 350 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 351 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 352 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 353 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 354 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 355 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.5.1 ISRAEL
      • 11.5.1.1 Financial support by government to drive market
    • TABLE 356 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 357 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 358 ISRAEL: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 359 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 360 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 361 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 362 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 363 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 364 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)
    • 11.5.2 OTHER COUNTRIES
    • TABLE 365 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 366 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION)
    • TABLE 367 OTHER COUNTRIES: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 368 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION)
    • TABLE 369 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION)
    • TABLE 370 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION)
    • TABLE 371 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION)
    • TABLE 372 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION)
    • TABLE 373 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION)

12 COMPETITIVE LANDSCAPE

  • 12.1 OVERVIEW
  • 12.2 STRATEGIES ADOPTED BY KEY PLAYERS
    • FIGURE 25 KEY DEVELOPMENTS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2019-2022
  • 12.3 MARKET SHARE ANALYSIS
    • FIGURE 26 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021
    • TABLE 374 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DEGREE OF COMPETITION
  • 12.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2019-2021
  • 12.5 COMPANY EVALUATION QUADRANT
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • FIGURE 28 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION QUADRANT, 2021
  • 12.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 STARTING BLOCKS
    • 12.6.3 RESPONSIVE COMPANIES
    • 12.6.4 DYNAMIC COMPANIES
    • FIGURE 29 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2021
  • 12.7 REGIONAL FOOTPRINT OF COMPANIES
    • TABLE 375 REGIONAL FOOTPRINT OF COMPANIES IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET (2021)
  • 12.8 COMPETITIVE SCENARIO
    • TABLE 376 KEY PRODUCT LAUNCHES
    • TABLE 377 KEY DEALS
    • TABLE 378 OTHER KEY DEVELOPMENTS

13 COMPANY PROFILES

  • 13.1 KEY PLAYERS
  • (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
    • 13.1.1 PFIZER INC.
    • TABLE 379 PFIZER INC.: COMPANY OVERVIEW
    • FIGURE 30 PFIZER, INC.: COMPANY SNAPSHOT (2021)
    • 13.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • TABLE 380 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
    • FIGURE 31 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
    • 13.1.3 DIVI'S LABORATORIES LIMITED
    • TABLE 381 DIVI'S LABORATORIES LIMITED: COMPANY OVERVIEW
    • FIGURE 32 DIVI'S LABORATORIES LIMITED: COMPANY SNAPSHOT (2021)
    • 13.1.4 VIATRIS INC.
    • TABLE 382 VIATRIS INC.: COMPANY OVERVIEW
    • FIGURE 33 VIATRIS INC.: COMPANY SNAPSHOT (2021)
    • 13.1.5 NOVARTIS AG
    • TABLE 383 NOVARTIS AG: COMPANY OVERVIEW
    • FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2021)
    • 13.1.6 SANOFI
    • TABLE 384 SANOFI: COMPANY OVERVIEW
    • FIGURE 35 SANOFI: COMPANY SNAPSHOT (2021)
    • 13.1.7 BOEHRINGER INGELHEIM
    • TABLE 385 BOEHRINGER INGELHEIM: COMPANY OVERVIEW
    • FIGURE 36 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2021)
    • 13.1.8 BRISTOL-MYERS SQUIBB
    • TABLE 386 BRISTOL-MYERS SQUIBB: COMPANY OVERVIEW
    • FIGURE 37 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2021)
    • 13.1.9 ELI LILLY AND COMPANY
    • TABLE 387 ELI LILLY AND COMPANY: COMPANY OVERVIEW
    • FIGURE 38 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2021)
    • 13.1.10 GLAXOSMITHKLINE PLC
    • TABLE 388 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW
    • FIGURE 39 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2021)
    • 13.1.11 MERCK & CO., INC.
    • TABLE 389 MERCK & CO., INC.: COMPANY OVERVIEW
    • FIGURE 40 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)
    • 13.1.12 ABBVIE INC.
    • TABLE 390 ABBVIE INC.: COMPANY OVERVIEW
    • FIGURE 41 ABBVIE INC.: COMPANY SNAPSHOT (2021)
    • 13.1.13 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 391 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
    • FIGURE 42 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021)
    • 13.1.14 ASTRAZENECA
    • TABLE 392 ASTRAZENECA: COMPANY OVERVIEW
    • FIGURE 43 ASTRAZENECA: COMPANY SNAPSHOT (2021)
    • 13.1.15 DR. REDDY'S LABORATORIES LTD.
    • TABLE 393 DR. REDDY'S LABORATORIES LTD.: COMPANY OVERVIEW
    • FIGURE 44 DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT (2021)
    • 13.1.16 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • TABLE 394 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
    • FIGURE 45 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
    • 13.1.17 CIPLA INC.
    • TABLE 395 CIPLA INC.: COMPANY OVERVIEW
    • FIGURE 46 CIPLA INC.: COMPANY SNAPSHOT (2021)
    • 13.1.18 AUROBINDO PHARMA
    • TABLE 396 AUROBINDO PHARMA: COMPANY OVERVIEW
    • FIGURE 47 AUROBINDO PHARMA LTD.: COMPANY SNAPSHOT (2021)
    • 13.1.19 EVONIK INDUSTRIES AG
    • TABLE 397 EVONIK INDUSTRIES AG: COMPANY OVERVIEW
    • FIGURE 48 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2021)
  • *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
  • 13.2 OTHER PLAYERS
    • 13.2.1 API PHARMA TECH
    • 13.2.2 BDR PHARMACEUTICALS INTERNATIONALS PVT. LTD.
    • 13.2.3 SREEPATHI PHARMACEUTICALS LIMITED
    • 13.2.4 SHILPA MEDICARE LIMITED

14 APPENDIX

  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS